**Supplementary Table S2: Laboratory Abnormalities (≥ 15%)a in the Safety Populationb**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Glasdegib+LDAC** | | | **LDAC** | | |
| **Laboratory Abnormality** | **N** | **Any grade %** | **Grade ≥ 3**  **%** | **N** | **Any grade**  **%** | **Grade ≥ 3**  **%** |
| Creatinine increased | 81 | 96 | 1 | 40 | 80 | 5 |
| Hyponatremia | 81 | 54 | 7 | 39 | 41 | 8 |
| Hypomagnesemia | 81 | 33 | 0 | 39 | 23 | 0 |
| AST increased | 80 | 28 | 1 | 40 | 23 | 0 |
| Blood bilirubin increased | 80 | 25 | 4 | 39 | 33 | 3 |
| ALT increased | 80 | 24 | 0 | 40 | 28 | 3 |
| ALP increased | 80 | 23 | 0 | 40 | 28 | 3 |
| Hyperkalemia | 81 | 16 | 1 | 40 | 8 | 3 |
| CPK increased | 38 | 16 | 0 | 17 | 6 | 0 |
| Hypokalemia | 81 | 15 | 0 | 40 | 23 | 0 |

aMaximum severity based on the number of patients with available on-study laboratory data within the first 90 days.

bN= 125 adults with newly-diagnosed AML or HR-MDS treated with glasdegib+LDAC or LDAC alone.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine

phosphokinase